LS-106

• Description:

  LS-106 is an orally active and potent inhibitor against epidermal growth factor receptor (EGFR) . LS-106 exhibits antitumor activities both in vitro and in vivo. LS-106 inhibits the kinase activities of EGFR19del/T790M/C797S and EGFRL858R/T790M/C797S with IC50 values of 2.4 nmol/L and 3.1 nmol/L, respectively, which is more potent than Osimertinib (HY-15772) . LS-106 induces Apoptosis, suppresses cell proliferation of tumor cells harboring EGFR19del/T790M/C797S and leas to significant tumor regression in a C797S-mutant xenograft model[1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; EGFR

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ls-106.html

• Smiles:

  CP (C1=CC=CC=C1NC2=NC (NC3=CC=C (N4CCC (C) CC4) C (Br) =C3) =NC=C2Cl) (C) =O

• Molecular Formula:

  C24H28BrClN5OP

• Molecular Weight:

  548.84

• References & Citations:

  [1]Liu Y, et al. LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo. Cancer Sci. 2022 Feb;113 (2) :709-720.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported